The oral presentation “Islet-Targeted GLP-1 Receptor Agonist Gene Therapy Reduces Fat and Improves ... patients with adequately controlled T2D on at least one glucose lowering agent (GLA). Fractyl ...

Diabetes and weight-loss drug tirzepatide (Mounjaro, Zepbound) was listed as a contributing factor in the death of a 58-year-old nurse from Scotland who died of multiple organ failure, septic shock, ...

The oral presentation "Islet-Targeted GLP-1 Receptor Agonist Gene Therapy Reduces Fat ... with T2D who are inadequately controlled on any glucose lowering agent, REVITALIZE-1, is currently enrolling ...

Pemvidutide has the potential to be the first incretin agent to achieve statistical significance in MASH ... indications for ...

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new recommendations.

Stroke survivors who took GLP-1 or SGLT2 medications had a 74% lower risk of death, according to a preliminary study being presented at the American Heart Association's annual Scientific Sessions, set ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...